Starpharma Interim Report and Half-Year Financial Results

Starpharma receives $3.7M R&D tax incentive refund

Shareholder Update February 2018

Starpharma to commence DEP® cabazitaxel phase 1/2 trial

VivaGel® BV treatment clinical submission under rolling submission


Starpharma Holdings Limited is a world leader in the development of dendrimer products for pharmaceutical, life-science and other applications.

Starpharma’s lead products are based on VivaGel® (SPL7013, astodrimer sodium), a proprietary dendrimer which has antimicrobial properties.  VivaGel® formulated as a water based gel and delivered vaginally has TGA and EU regulatory approval for bacterial vaginosis (BV).  Starpharma has also developed an antiviral condom which uses VivaGel® in the lubricant, which is available in Australia and Canada under the Lifestyles® Dual Protect™ brand. Starpharma has a number of license agreements to market the VivaGel® condom in other regions, including China and Japan (Okamoto). 


In the wider pharmaceutical field, Starpharma has both partnered and internal programs in Drug Delivery. Starpharma’s DEP® drug delivery platform has demonstrated reproducible preclinical benefits across multiple internal and partnered DEP® programs, including improved efficacy, safety and survival. Starpharma has two internal DEP® products – DEP® docetaxel and DEP® cabazitaxel - in clinical development in patients with solid tumours, and further DEP® products approaching clinical development. Starpharma’s partnered DEP® programs include a multiproduct DEP® licence with AstraZeneca, which involves the development and commercialisation of two novel oncology compounds, with potential to add more


© Starpharma Holdings Limited 2017